Groundbreaking findings from the landmark CLEAR (Clinical trial Comparing Lenvatinib with Ecerolimus or Pembrolizumab in ...

Dr. Catherine Wu discussed the unique aspects of clear cell renal cell carcinoma and the challenges of targeting it with a ...

Dr. Katy Beckermann discusses how a Fotivda and Opdivo combination for renal cell carcinoma compared with Fotivda alone based ...

Casdatifan targets a transcription factor that binds with other proteins to switch off the body’s anti-inflammatory ...

Casdatifan’s progression-free survival benefits could help differentiate it from Merck’s Welireg in the kidney cancer arena, ...

Neoantigen-targeting PCVs are highly immunogenic in high-risk clear cell RCC and can target key driver mutations and induce antitumor immunity.

Kathryn Beckermann, MD, PhD, discusses the patient-reported outcomes for tivozanib plus nivolumab from the phase 3 TiNivo-2 ...

Exelixis reaffirmed its 2025 sales guidance of $2.15-$2.25 billion and reported sustained long-term efficacy for Cabometyx in ...

At AGBT, Singular Genomics presented data demonstrating the G4X platform’s robust integrated multiomic performance. Immune-oncology-focused lung, kidney, colon, and breast panels showed high ...

Belzutifan plus cabozantinib maintained durable antitumor activity in advanced clear cell renal cell carcinoma, per phase 3 ...

The Odessa American is the leading source of local news, information, entertainment and sports for the Permian Basin.